| HOME >> MEDICINE >> TECHNOLOGY |
NEW BRUNSWICK, N.J., April 28, 2011 /PRNewswire-FirstCall/ -- At Johnson & Johnson's Annual Meeting of Shareholders today, Chairman and CEO Bill Weldon provided an in-depth look at the steps being taken to address recent quality issues, to restore confidence and trust in the company and its products, and to continue building on its 125-year legacy of meeting the world's health care needs.
Weldon, along with Alex Gorsky and Sheri McCoy, vice-chairmen of Johnson & Johnson's Executive Committee, highlighted patient stories and innovations that promise to help people lead healthier lives; products and pipelines to address conditions such as Alzheimer's disease, stroke, diabetes, prostate cancer and HIV; and efforts to meet the growing demand for health care in emerging markets.
Weldon began by highlighting Johnson & Johnson's announcement yesterday about the definitive agreement to acquire Synthes, Inc., a premier global developer and manufacturer of orthopaedics devices. He described the agreement as "consistent with our long-term strategy to strengthen our leadership position across important health care markets – in this case, the $37 billion global orthopaedics market."
125 Years of Caring
Setting context, Weldon said, "One hundred twenty five years ago, three brothers shared knowledge of Joseph Lister's theories about infection and a dream that they could save lives in the nation's hospitals." He said, "Now, the same kind of spirit, commitment and innovation motivates over 114,000 employees of Johnson & Johnson. We are not perfect. Yet every day our employees pursue their dreams of positively impacting human lives in more ways than our founders could have possibly imagined."
McNeil Consumer Healthcare Progress
Early in the meeting, Weldon expressed his personal disappointment in the series of recalls that have occurred over the past year at the company's M
'/>"/>
| SOURCE Johnson & Johnson Copyright©2010 PR Newswire. All rights reserved |